Form 4: Catalyst Pharma Director Converts RSUs to Shares

Catalyst Pharmaceuticals Director Donald A. Denkhaus converted 1,413 restricted stock units into common stock on December 8, 2025, increasing his direct holdings.

Summary

• Donald A. Denkhaus, a Director of Catalyst Pharmaceuticals, Inc. (CPRX), converted 1,413 Restricted Stock Units (RSUs) into common stock.
• This transaction occurred on December 8, 2025, representing the vesting of the second tranche of his RSU awards.
• Following the conversion, Denkhaus directly owns 497,439 shares of common stock.
• He continues to hold 179,497 Restricted Stock Units.
• The shares of common stock were delivered to the reporting person within sixty days of vesting.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine insider transaction (RSU conversion), which is expected. The increase in direct share ownership by a director can be seen as a minor positive signal of confidence.

Positives

• Director Donald A. Denkhaus increased his direct ownership of common stock by 1,413 shares, which can signal continued confidence in the company's future.

Future Outlook

The vesting schedule indicates future share deliveries to the reporting person, with the final tranche of Restricted Stock Units set to vest on December 8, 2026.

Industry Context

This is a routine insider transaction for a director converting previously granted equity awards, common practice in the pharmaceutical industry for executive compensation and retention.

Comparison to Industry Standards

• The conversion of Restricted Stock Units into common stock upon vesting is a standard practice for executive compensation across various industries, including pharmaceuticals. This aligns with typical equity incentive plans designed to align management interests with shareholder value over time.

Stakeholder Impact

• Shareholders: The director's increased direct ownership aligns his interests more closely with shareholders.

Next Steps

• The remaining 1/3rd tranche of Restricted Stock Units is scheduled to vest on December 8, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine conversion of Restricted Stock Units by a director, which is an expected part of executive compensation. It does not provide new information that would fundamentally alter the investment thesis for Catalyst Pharmaceuticals, Inc. While the increased direct ownership by a director is a minor positive, it is not significant enough to warrant a change in recommendation based solely on this filing.

Keywords

Catalyst Pharmaceuticals, CPRX, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Director Stock Ownership, Donald A. Denkhaus